Back to Newsroom

International Stem Cell Corporation Submits Remaining Requested Safety Study Report for Clinical Trial Authorization

CARLSBAD, CA–(Marketwired – July 30, 2015) – International Stem Cell Corporation (ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today the submission of the final safety (tumorigenicity) and biodistribution study report that has been requested by the Australian Therapeutics Good Administration (TGA) prior to initiation of the company’s Phase 1/2a clinical trial for the treatment of Parkinson’s Disease.
Click here to read more